Quantum-Si

Quantum-Si, Inc. develops a protein sequencing platform of proteomics. It offers single molecule analysis, and democratizing its use by providing researchers and clinicians access to the proteome. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Guilford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quantum-Si reports mixed Q4 results, eyes growth with Carbon launch

Quantum-Si's Q4 2022 earnings call showcased a mix of financial challenges and operational successes. The company's focus on innovation, product development, and commercialization efforts positions it well for future growth and impact in the healthcare industry.

Quantum-Si reports Q1 revenue growth, plans marketing expansion

Quantum-Si's Q1 2023 performance showed promising revenue and customer orders, but challenges persist with high operating expenses leading to an EBITDA loss. The company's focus on innovation and market expansion presents growth opportunities in the coming quarters.

Quantum-Si faces revenue hurdles in Q2 2023 earnings call

Quantum-Si's Q2 2023 performance showed revenue and gross profit figures, but challenges in meeting expectations led to significant losses. The company's strengths lie in the commercial team's positive feedback and strategic hires, while opportunities exist in realignment and disciplined growth strategies. Addressing revenue challenges, R&D alignment, and customer feedback are key priorities for Quantum-Si.

Quantum-Si (QSI) reports Q3 revenue growth and eyes global expansion

Quantum-Si (QSI) shows promising progress in revenue growth, product innovation, and market interest, despite facing challenges in expenses and profitability.
The company's strategic focus on commercializing key products and expanding internationally presents significant growth opportunities in the coming quarters.
Overall, QSI's financial performance, product roadmap, and market strategies position it for future success, pending effective execution and cost management.

Quantum-Si reports Q4 loss, eyes growth with innovative sequencing

Quantum-Si's Q4 2023 performance reflects a focus on innovation and market expansion despite a net loss, with strong revenue guidance for 2024.
The company's strategic strengths lie in its disruptive technology, product development initiatives, and market positioning in key regions.
Challenges in managing expenses and achieving profitability underscore the need for operational efficiency and competitive differentiation.
Amidst challenges, Quantum-Si has opportunities to drive growth through new product launches, market expansion, and meeting increasing market demand.

Quantum-Si reports revenue growth and strategic priorities for 2024

Quantum-Si's Q2 2024 performance showed revenue growth and improved net loss.
The company's strengths lie in financial reserves, guidance, and strategic priorities.
Challenges include managing expenses and balancing financial strength with innovation.
Opportunities arise from new board additions, technology potential, and market focus.

Quantum-Si reports Q3 revenue miss, eyes growth opportunities ahead

Quantum-Si's Q3 2024 performance reflects revenue challenges but anticipates improvement in Q4, supported by strong cash reserves.
The company's strategic strengths include leadership appointments, industry recognition, and initiatives to drive technology adoption.
Addressing challenges in deal execution, cost management, and revenue generation will be crucial for Quantum-Si's financial health and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum-Si, Inc. engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing, the ability to sequence proteins in a massively parallel fashion. It can be used for the study of nucleic acids. Its platform includes Carbon automated sample preparation instrument, Platinum NGPS instrument, Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits. Combined with its first-to-market, next-generation protein sequencer™, these enhancements enable: Increased sequencing performance with assay improvements, including the addition of a new amino acid recognizer; Ability to identify unkn.

Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

Quantum-Si is about to move from a controlled launch to a full scale commercial launch of its first product. It will be a groundbreaking device, a desktop Proteome sequencer at a fraction of the price of competing technology. If the product is successful, QSI stock is likely significantly undervalued.

Quantum-Si: Commercial Lift Imminent

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein se.

Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si expands global reach with addition of new distributor.

Quantum-Si Expands Global Reach with Addition of New Distributor

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows.

Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows

Quantum-Si Incorporated (QSI) Q3 2023 Earnings Call Transcript

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Third Quarter 2023 Financial Results.

Quantum-Si Reports Third Quarter 2023 Financial Results

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards.

Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate at Two Upcoming Investor Conferences.

Quantum-Si to Participate at Two Upcoming Investor Conferences

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023.

Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023

Quantum-Si incorporated is a pioneering company in the field of proteomics with its innovative Platinum platform. The company's revenue model is still in its early stages, making it a highly speculative investment. QSI's valuation is challenging but has explosive revenue potential in the growing proteomics market.

Quantum-Si: Highly Speculative With A Strong Appeal

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Third Quarter 2023 Financial Results on November 9, 2023.

Quantum-Si to Report Third Quarter 2023 Financial Results on November 9, 2023

--(BUSINESS WIRE)--Quantum-Si Hosts Webinar on Advances in Protein Identification and Characterization.

CORRECTING AND REPLACING Quantum-Si Hosts Webinar on Advances in Protein Identification and Characterization

Quantum-Si Hosts Webinar on Advances in Protein Identification and Characterization

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Present at The Festival of Genomics & Biodata 2023 in Boston, Massachusetts.

Quantum-Si to Present at The Festival of Genomics & Biodata 2023 in Boston, Massachusetts

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors.

Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors

Quantum-SI released its Q2 2023 earnings report, which showed lower-than-expected revenue and reduced forward guidance. The company shelved its carbon product and identified problems with its AI software. Despite the market's negative reaction, the company has strong potential in the protein sequencing market and has a solid financial position.

Quantum-Si: Market Overreaction May Provide An Excellent Entry Point

Quantum-Si stock beat on earnings this morning, but suffered a sales miss. Worse than that, sales actually slowed down between Q1 and Q2.

Why Quantum-Si Stock Crashed 35% Today

Quantum-Si incorporated (NASDAQ:QSI ) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants Juan Avendano - Head, Investor Relations Jeff Hawkins - Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Yuan Zhi - B. Riley Swayampakula Ramakanth - H.C.

Quantum-Si incorporated (QSI) Q2 2023 Earnings Call Transcript

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Second Quarter 2023 Financial Results.

Quantum-Si Reports Second Quarter 2023 Financial Results

Applied DNA Sciences

Broadwind Energy

Investors tend to have a love-hate relationship with penny stocks. On the one hand, they offer the possibility of fascinating returns, due to the underlying stock's volatility, and the ability to purchase large shares with relatively little capital.

3 Penny Stocks to Buy Before the Breakout

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the Canaccord Genuity 43rd Annual Growth Conference.

Quantum-Si to Participate in the Canaccord Genuity 43rd Annual Growth Conference

The medical-equipment maker specializes in equipment for the large-scale studying of proteins. The company went public in 2021.

Why Shares of Quantum-Si Jumped This Week

One of Cathie Wood's ETFs has been buying startup Quantum-Si again. This company has promising technology, but it generates no meaningful revenue yet.

Is Cathie Wood Stock Quantum-Si a Buy?

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Second Quarter 2023 Financial Results on August 7, 2023.

News for Quantum-Si Stock (QSI)